Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Contract win

1 May 2014 07:00

RNS Number : 0079G
Instem plc
01 May 2014
 



 

 

Instem plc

("Instem" or the "Company")

 

Contract Win

 

Instem's Provantis and Centrus solutions selected by WIL Research to replace and enhance its toxicology systems and processes worldwide

 

Instem (AIM: INS.L), a leading provider of IT solutions to the global early development healthcare market, announces today that it has been selected by WIL Research ("WIL") as its exclusive non-clinical technology partner, to optimise study-related processes at all WIL worldwide sites.

 

Key Facts

· Instem technology to replace all existing study management systems at WIL Research

· WIL Research selects all Provantis Preclinical Study Management modules

· Using Instem's Centrus-submit solution, WIL Research will become SEND (Standard for Exchange of Nonclinical Data) enabled

· WIL Research to leverage Instem's market leading SaaS model for worldwide deployment

 

WIL Research has approximately 1,200 staff offering a blend of technical and regulatory expertise in discovery support, product safety toxicological research, metabolism, bioanalytical chemistry, analytical chemistry and formulation services.

 

WIL Research has chosen Instem's entire Provantis software suite, including its Logbook ELN solution for paper form replacement, as part of a multi-year project. Instem's Toxicology Resource Planning ("TRP") solution is also a key element of the Provantis deployment, increasing efficiencies by enabling WIL Research to plan and manage studies and programs, allocate resources, benchmark against past studies and plan workloads for the future.

WIL Research has additionally selected Instem's Centrus-submit™ solution to support SEND, the standardised reporting format for nonclinical data. The submit solution suite converts data from any source system into SEND files and allows sponsors, CROs and regulators such as the FDA to share, visualise and analyse study data more efficiently.

 

David Spaight, Chief Executive Officer at WIL Research, commented: "We are delighted to announce our enhanced partnership with Instem on a global level to deploy a comprehensive solution for toxicology data collection and management across our facilities situated in the United States, the Netherlands and in France. By leveraging our existing experience with Provantis in France, this expanded platform will support growing demand from our clients requiring a common and seamless multi-site global study management solution."

 

Phil Reason, CEO of Instem plc, commented: "WIL's selection of Instem's technology to replace all of its existing study management systems is a significant endorsement of the quality of our solutions. WIL has been a valued customer of Instem for 7 years and we are excited that it has chosen to extend that relationship as part of the technology-driven transformation that it is embarking upon. Instem has already secured SaaS revenues in excess of $2 million per annum and this provides further evidence of the attractiveness of this solution to clients. Demand for our offering remains strong and the growing proportion of SaaS contracts is leading to increasing visibility going forward."

 

 

 

 

 

 

For further information, please contact:

 

Instem plc

www.instem.com

Phil Reason, CEO

Tel: +44 (0) 1785 825 600

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: +44 (0) 20 7496 3000

Richard Lindley

 

Nick Owen

 

 

 

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780 or instem@walbrookpr.com

Bob Huxford

Mob: +44 (0)7747 635 908

Helen Cresswell

Mob: +44 (0)7841 917 679

 

 

 

About WIL Research

WIL Research is an interdisciplinary non-clinical contract research organisation providing product safety and toxicological assessment research and services to the international pharmaceutical, biotechnology, chemical, agricultural, veterinary, food and consumer products industries.

 

Find out more about WIL Research at www.wilresearch.com

 

 

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutionsfor data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledgethrough the extraction and harmonisation of actionable scientific information.

 

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

 

To learn more about Instem solutions and its mission, please visit www.instem.com.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAQKKDBCBKDPQN
Date   Source Headline
18th May 20071:09 pmRNSRule 8.3- Intnl Nuclear Sol.
17th May 20075:02 pmRNSRule 8.3- Int Nuclear Sol
17th May 20073:25 pmBUSRule 8.3 - International Nuclear Solutions
16th May 20079:13 amRNSNotification of shares
14th May 200710:40 amRNSEGM ADJOURNMENT
11th May 200711:48 amRNSHolding(s) in Company
11th May 20079:42 amRNSHolding(s) in Company
10th May 20073:04 pmBUSRule 8.3 - International Nuclear Solution
10th May 20071:44 pmRNSRule 8.3-Int'l Nuclear Sol
1st May 200711:44 amRNSHolding(s) in Company
1st May 200710:00 amRNSRule 8.3- Intnl Nuclear Sols
30th Apr 20074:26 pmRNSHolding(s) in Company
26th Apr 20073:29 pmBUSRule 8.3 - International Nuclear Solutions
26th Apr 20073:07 pmRNSRule 8.3-Intl Nuclear Sol
26th Apr 20072:28 pmRNSRule 8.3- Intl Molybdenum plc
25th Apr 20073:17 pmBUSRule 8.3 - International Nuclear Solutions
25th Apr 200712:41 pmRNSRule 8.3- Int'l Nuclear Sol
23rd Apr 20071:34 pmRNSRule 8.3-Int. Nuclear
20th Apr 20074:30 pmRNSPosting of Scheme Document
18th Apr 20073:32 pmBUSRule 8.3 - International Nuclear Solutions
18th Apr 200710:09 amRNSRule 8.3- Intnl Nuclear Sol.
12th Apr 20073:05 pmBUSRule 8.3 - International Nuclear Solutions
5th Apr 20075:02 pmBUSRule 8.3 - International Nuclear Solution
5th Apr 200711:39 amRNSRule 8.3- Intnl Nuclear Sol.
5th Apr 200711:00 amRNSRule 8.3- Intnl Nuclear Sol
4th Apr 20074:21 pmRNSRule 8.3- Int Nuclear Sol
4th Apr 20073:30 pmBUSRule 8.3 - International Nuclear Solutions
4th Apr 200711:47 amRNSRule 8.3- Intnl Nuclear Sol.
4th Apr 20077:02 amRNSRecommended Cash Offer
4th Apr 20077:02 amRNSScheme of arrangement
3rd Apr 20075:29 pmRNSCorrection to Prelims
30th Mar 20073:13 pmBUSRule 8.3 - International Nuclear Solutions
29th Mar 20073:21 pmBUSRule 8.3 - INTERNATIONAL NUCLEAR SOLUTIONS
28th Mar 20073:27 pmRNSRule 8.3-Int Nuclear Sol
27th Mar 20077:02 amRNSFinal Results
26th Mar 200711:37 amRNSRule 8.3- Intnl Nuclear Sol.
23rd Mar 20073:26 pmBUSRule 8.3 - International Nuclear Solutions
19th Mar 200711:06 amRNSRule 8.3- Intnl Nuclear Sol.
8th Mar 200711:59 amRNSRule 8.3- Intnl Nuclear Sol.
20th Feb 20072:34 pmBUSRule 8.3 - Internationa Nuclear Solutions
16th Feb 200710:50 amRNSRule 8.3- Intnl Nuclear Sol.
12th Feb 200712:06 pmRNSRule 8.3- Intnl Nuclear Sol.
7th Feb 20073:18 pmBUSRule 8.3 - International Nuclear Solutions
1st Feb 200710:40 amRNSRule 8.3- Intnl Nuclear Sol.
30th Jan 200711:01 amRNSRule 8.3- Intnl Nuclear Sol.
29th Jan 20072:39 pmRNSRule 8.3- Intnl Nuclear Sol.
29th Jan 20071:51 pmRNSRule 8.3- Intnl Nuclear Sol.
29th Jan 200711:00 amRNSRule 8.3- Intnl Nuclear
26th Jan 20075:45 pmRNSShare Interest
26th Jan 20073:20 pmRNSRule 8.1- Int Nuclear Sols

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.